Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence

Abstract

Purpose To evaluate the efficacy and tolerability of mirabegron in females with overactive bladder (OAB) symptoms after surgical treatment for stress urinary incontinence (SUI).Materials and Methods The study was conducted with a prospective, randomized and double-blinded design. 62 patients over the age of 40 who met the inclusion-exclusion criterias of the study were enrolled and randomly divided into two groups as Group A (mirabegron 50mg) and B (solifenacin 5mg). Patients were compared based on efficacy of treatment [Patient Perception of Bladder Condition (PPBC) scale and micturition diaries], safety of treatment (heart rate, systolic and diastolic blood pressure, adverse events), number of micturitions per day, patient’s satisfaction status after treatment [Visual Analog Scale(VAS)] and quality of life.Results The mean age of the population was 48.2±3.8 years and the duration of OAB symptoms was 5.9±2.9 months. Baseline values for the mean number of micturitions, volume voided in each micturition, nocturia episodes, urgency and urgency incontinence episodes were 15.3±0.34, 128±3.88mL, 3.96±1.67, 5.72±1.35 and 4.22±0.69, respectively. After treatment, values for these parameters were 11.7±0.29, 164.7±2.9mL, 2.25±0.6, 3.38±0.71, 2.31±0.49 respectively. Quality of life score, symptom bother score, VAS for treatment satisfaction score, PPBC score after treatment were 66.1±0.85, 43.7±0.77, 4.78±0.14, 4.78±0.14, respectively. There were no significant differences between two groups on any parameter. However, mirabegron showed better tolerability than solifenacin, particularly after 6 months.Conclusion Mirabegron is safe, effective and tolerable in the long-term treatment of females with OAB symptoms after surgery for stress urinary incontinence.

Efficacy of intravaginal electrical stimulation added to bladder training in women with idiopathic overactive bladder: A prospective randomized controlled trial

“…Overactive bladder (OAB) is defi ned as urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence (UUI) according to the International Continence Society (1). Many drugs such as oral anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) and fi rst-line conservative therapeutic options are commonly used for UUI and OAB, including electrical stimulation (ES), pelvic fl oor muscle (PFM) training and behavioral therapies such as lifestyle changes and bladder training (BT) (1)(2)(3)(4)(5)(6). BT involves a systematic voiding regimen to lengthen the interval between voids until an acceptable pattern has been restored (2,4,5).…”

“…and percutaneous ES (of the tibial nerve, electroacupuncture, etc.) (6). Intravaginal ES (IVES) is a conservative treatment option, described more than 40 years ago.…”

Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder

“…It is mainly responsible for promoting human detrusor relaxation and urine storage in the bladder [10] . Compared with anticholinergic agents, plenty of randomized controlled trials have reported that mirabegron could have better efficacy in monotherapy of the OAB symptoms [11–13] . However, they are also associated with specific side effects, including hypertension, constipation, dry mouth, tachycardia, and UTI [14] .…”

Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors

“…Mete et al reported that symptoms including hypertension and palpitations can be relieved after withdrawal of the drug. 18 The quality of life among patients with other AE remained unaffected.…”

“… 17 Mirabegron has demonstrated significant efficacy and safety in the treatment of lower urinary tract symptoms (LUTs) following stress urinary incontinence surgery in women and OAB due to benign prostatic hyperplasia with bladder outlet obstruction in men. 18 , 19 However, its efficacy against symptoms of local side effects after TURBT with subsequent BCG immunotherapy remains unexplored.…”